Allogene Therapeutics
Cesar Sommer is an experienced biomedical scientist currently serving as Executive Director at Allogene Therapeutics, where prior roles included Senior Director, Director, Associate Director, and Principal Scientist, with a focus on cancer immunotherapy involving CAR T cells and bispecific antibodies. At Pfizer, Cesar Sommer held the position of Principal Scientist and Senior Scientist, concentrating on the preclinical development of CAR-T cell therapies and optimizing gene editing techniques. Earlier, as a Postdoctoral Fellow at Boston University, significant contributions included developing a reprogramming platform for clinical-grade iPSC lines and exploring cancer mechanisms using genetically-engineered cell lines. Cesar Sommer holds a Ph.D. in Molecular Genetics from UFSCar and a B.S. in Genetics from Universidad Nacional de Misiones.
This person is not in the org chart
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.